



## The Gut Microbiome in Colorectal Cancer

Guest Editors:

**Prof. Dr. Shahid Umar**

Department of Surgery, Medical  
Center, Kansas City, KS 66160,  
USA

**Prof. Dr. Mazin Al-Kasspoles**

Peritoneal Surface Malignancy  
Program, Division of Surgical  
Oncology, Department of  
Surgery, The University of Kansas  
Health System, Kansas City, MO  
66160, USA

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Significant advances have been made in associating individual bacterial species to consensus molecular subtypes (CMS) of CRC. It is expected that the development of therapeutics based on the microbial association with CMS will likely facilitate the translation of molecular subtypes into the clinic for CRCs and potentially other malignancies.

The microbiota niche in colorectal cancer can also modify the efficacy and toxicity profile of different oncotherapeutic treatment modalities from chemoradiotherapy to immunotherapy. Conversely, each of these treatment modalities has numerous effects on the gastrointestinal flora, causing changes in the gut microbial community that affect host morbidity and mortality. A closer look at the cross-talks between the commensals, epithelial cells, immune regulators, and so on needs to be established with more substantiated studies. The recurrence of chemoresistant disease following therapy undoubtedly provides the impetus for morbidity and mortality; however, the role of the gut microbiome in drug resistance remains to be fully investigated.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Maurizio Battino**

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

*Diseases* is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

*Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

*Diseases* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/diseases  
diseases@mdpi.com  
X@Diseases\_MDPI